Search

Your search keyword '"Yáñez, Lucrecia"' showing total 229 results
Start Over Author "Yáñez, Lucrecia"
229 results on '"Yáñez, Lucrecia"'

1. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Author

Abrisqueta, Pau, González-Barca, Eva, Ferrà, Christelle, Ríos-Herranz, Eduardo, Fernández de la Mata, Margarita, Delgado, Julio, Andreu, Rafael, Hernández-Rivas, José Ángel, Terol, María José, Navarro, Almudena, Vidriales, M. Belén, Baltasar, Patricia, De la Serna, Javier, Ramírez, Ángel, Ballester, Carmen, Moreno, Carol, García-Marco, José Antonio, Córdoba, Raúl, Yáñez, Lucrecia, Casado, Luís Felipe, González, Marcos, and Bosch, Francesc

Published
2024
Full Text
View/download PDF

2. Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party

Author

Penack, Olaf, Tridello, Gloria, Salmenniemi, Urpu, Martino, Rodrigo, Khanna, Nina, Perruccio, Katia, Fagioli, Franca, Richert-Przygonska, Monika, Labussière-Wallet, Hélène, Maertens, Johan, Jubert, Charlotte, Aljurf, Mahmoud, Pichler, Herbert, Kriván, Gergely, Kunadt, Desiree, Popova, Marina, Gabriel, Melissa, Calore, Elisabetta, Blau, Igor Wolfgang, Benedetti, Fabio, Itäla-Remes, Maija, de Kort, Elizabeth, Russo, Domenico, Faraci, Maura, Ménard, Anne-Lise, Borne, Peter von dem, Poiré, Xavier, Yesilipek, Akif, Gozdzik, Jolanta, Yeğin, Zeynep Arzu, Yañez, Lucrecia, Facchini, Luca, Van Gorkom, Gwendolyn, Thurner, Lorenz, Kocak, Ulker, Sampol, Antònia, Zuckerman, Tsila, Bierings, Marc, Mielke, Stephan, Ciceri, Fabio, Wendel, Lotus, Knelange, Nina, Mikulska, Malgorzata, Averbuch, Dina, Styczynski, Jan, Camara, Rafael de la, and Cesaro, Simone

Published
2024
Full Text
View/download PDF

3. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Author

Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Al-Shemari, Salem, Aurran-Schleinitz, Thérèse, Bacchiarri, Francesca, Bellido, Mar, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofia, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, Maria, Donaldson, David, Santos, Gimena Dos, Dreta, Barbara, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón-y-Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José-Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Laribi, Kamel, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, Maria, Konstantinou, Eliana, Koren-Michowitz, Maya, Kotsianidis, Ioannis, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, Lopez-Garcia, Alberto, Marquet, Juan, Martin-Rodríguez, Lucia, Maynadié, Marc, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Miras, Fatima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, Maria, Papajík, Tomas, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martin, Smirnova, Svetlana, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Tadmor, Tamar, Tomic, Kristina, Tse, Eric, Vassilakopoulos, Theodoros, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Panagiotidis, Panagiotis, Popov, Viola Maria, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine, Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2023
Full Text
View/download PDF

5. Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study

Author

Puerta-Alcalde, Pedro, Monzó-Gallo, Patricia, Aguilar-Guisado, Manuela, Ramos, Juan Carlos, Laporte-Amargós, Júlia, Machado, Marina, Martin-Davila, Pilar, Franch-Sarto, Mireia, Sánchez-Romero, Isabel, Badiola, Jon, Gómez, Lucia, Ruiz-Camps, Isabel, Yáñez, Lucrecia, Vázquez, Lourdes, Chumbita, Mariana, Marco, Francesc, Soriano, Alex, González, Pedro, Fernández-Cruz, Ana, Batlle, Montserrat, Fortún, Jesús, Guinea, Jesús, Gudiol, Carlota, García, Julio, Ruiz Pérez de Pipaón, Maite, Alastruey-Izquierdo, Ana, and Garcia-Vidal, Carolina

Published
2023
Full Text
View/download PDF

6. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

Author

Kwon, Mi, Gómez-Centurión, Ignacio, Oarbeascoa, Gillen, Torres, Melissa, Martinez, Ariadna Perez, Suarez-Lledó, Maria, Chinea, Anabelle, Cascón, Maria Jesus Pascual, Vazquez, Lourdes, Espigado, Ildefonso, Izquierdo, Isabel, Parody, Rocio, Cadenas, Irene Garcia, Calbacho, Maria, Sierra, Pedro Gonzalez, Heras, Inmaculada, Yañez, Lucrecia, Torrent, Anna, Bautista, Guiomar, Gonzalez, Soledad, Roldan, Elisa, Vallejo, Juan Carlos, Bailen, Rebeca, Borrero, Asunción, Lopez-Jiménez, Javier, Casas, Maria Angeles Cuesta, and Solano, Carlos

Published
2024
Full Text
View/download PDF

7. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

Author

Shouval, Roni, Fein, Joshua A., Cho, Christina, Avecilla, Scott T., Ruiz, Josel, Tomas, Ana Alarcon, Sanchez-Escamilla, Miriam, Flores, Nerea Castillo, Yáñez, Lucrecia, Barker, Juliet N., Dahi, Parastoo, Giralt, Sergio A., Geyer, Alexander I., Gyurkocza, Boglarka, Jakubowski, Ann A., Lin, Richard J., O'Reilly, Richard J., Papadopoulos, Esperanza B., Politikos, Ioannis, Ponce, Doris M., Sauter, Craig S., Scordo, Michael, Shaffer, Brian, Shah, Gunjan L., Sullivan, James P., Tamari, Roni, van den Brink, Marcel R.M., Young, James W., Nagler, Arnon, Devlin, Sean, Shimoni, Avichai, and Perales, Miguel-Angel

Published
2022
Full Text
View/download PDF

8. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Author

Abrisqueta, Pau, Loscertales, Javier, Terol, Maria José, Ramírez Payer, Ángel, Ortiz, Macarena, Pérez, Inmaculada, Cuellar-García, Carolina, Fernández de la Mata, Margarita, Rodríguez, Alicia, Lario, Ana, Delgado, Julio, Godoy, Ana, Arguiñano Pérez, José Mª, Berruezo, Mª José, Oliveira, Ana, Hernández-Rivas, José-Ángel, García Malo, Maria Dolores, Medina, Ángeles, García Martin, Paloma, Osorio, Santiago, Baltasar, Patricia, Fernández-Zarzoso, Miguel, Marco, Fernando, Vidal Manceñido, Mª Jesús, Smucler Simonovich, Alicia, López Rubio, Montserrat, Jarque, Isidro, Suarez, Alexia, Fernández Álvarez, Rubén, Lancharro Anchel, Aima, Ríos, Eduardo, Losada Castillo, María del Carmen, Pérez Persona, Ernesto, García Muñoz, Ricardo, Ramos, Rafael, Yáñez, Lucrecia, Bello, José Luis, Loriente, Cristina, Acha, Daniel, and Villanueva, Miguel

Published
2021
Full Text
View/download PDF

9. Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion—multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT

Author

Snarski, Emilian, Stringer, Jacqui, Mikulska, Małgorzata, Gil, Lidia, Tridello, Gloria, Bosman, Paul, Lippinkhof, Anne, Hoek, Jennifer, Karas, Michal, Zver, Samo, Lueck, Catherina, Blijlevens, Nicole, González, Iria, Ociepa-Wasilkowska, Małgorzata, Górka, Michał, Sánchez-Ortega, Isabel, Andersson, Inger, Yáñez, Lucrecia, Bekadja, Mohamed-Amine, and Styczynski, Jan

Published
2021
Full Text
View/download PDF

13. Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

Author

Royo-Cebrecos, Cristina, primary, Laporte-Amargós, Júlia, additional, Peña, Marta, additional, Ruiz-Camps, Isabel, additional, Garcia-Vidal, Carolina, additional, Abdala, Edson, additional, Oltolini, Chiara, additional, Akova, Murat, additional, Montejo, Miguel, additional, Mikulska, Malgorzata, additional, Martín-Dávila, Pilar, additional, Herrera, Fabián, additional, Gasch, Oriol, additional, Drgona, Lubos, additional, Morales, Hugo Manuel Paz, additional, Brunel, Anne-Sophie, additional, García, Estefanía, additional, Isler, Burcu, additional, Kern, Winfried V., additional, Palacios-Baena, Zaira R., additional, de la Calle, Guillermo Maestr, additional, Montero, Maria Milagro, additional, Kanj, Souha S., additional, Sipahi, Oguz R., additional, Calik, Sebnem, additional, Márquez-Gómez, Ignacio, additional, Marin, Jorge I., additional, Gomes, Marisa Z. R., additional, Hemmatii, Philipp, additional, Araos, Rafael, additional, Peghin, Maddalena, additional, Del Pozo, Jose L., additional, Yáñez, Lucrecia, additional, Tilley, Robert, additional, Manzur, Adriana, additional, Novo, Andrés, additional, Carratalà, Jordi, additional, and Gudiol, Carlota, additional

Published
2024
Full Text
View/download PDF

14. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy

Author

Jiménez-Ubieto, Ana, Grande, Carlos, Caballero, Dolores, Yáñez, Lucrecia, Novelli, Silvana, Hernández-Garcia, Miguel Teodoro, Manzanares, María, Arranz, Reyes, Ferreiro, José Javier, Bobillo, Sabela, Mercadal, Santiago, Galeo, Andrea, Jiménez, Javier López, Moraleda, José M., Vallejo, Carlos, Albo, Carmen, Pérez, Elena, Marrero, Carmen, Magnano, Laura, Palomera, Luis, Jarque, Isidro, Rodriguez, Antonia, Lorza, Leyre, Martín, Alejandro, Coria, Erika, López-Guillermo, Armando, Salar, Antonio, and José Lahuerta, Juan

Published
2019
Full Text
View/download PDF

15. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant

Author

Bento, Leyre, Bastida, José María, García-Cadenas, Irene, García-Torres, Estefania, Rivera, Daniel, Bosch-Vilaseca, Anna, De Miguel, Carlos, Martínez-Muñoz, María Esther, Fernández-Avilés, Francesc, Roldán, Elisa, Chinea, Anabelle, Yáñez, Lucrecia, Zudaire, Teresa, Vaz, Carlos Pinho, Espigado, Ildefonso, López, Javier, Valcárcel, David, Duarte, Rafael, Cabrera, Rafael, Herrera, Concepción, González-Porras, José Ramón, Gutiérrez, Antonio, Solano, Carlos, and Sampol, Antonia

Published
2019
Full Text
View/download PDF

16. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Author

Santos, Marta Fonseca, Almorox, Rebeca Bailen, Solan, Laura, Lopez, Oriana, Gallardo, Anabel, Garcia-Avila, Sara, Esquirol, Albert, Ferra, Christelle, Martin, Ana, Garcia, Abel, Perez, Estefania, Colorado, Mercedes, Cortes, Maria, Cabrero, Monica, Gayoso, Jorge, Yañez, Lucrecia, Pascual, Maria Jesus, Heras, Inmaculada de las, Diez, Jose Luis, Caballero, Maria Dolores, Kwon, Mi, and Corral, Lucia Lopez

Published
2022
Full Text
View/download PDF

17. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations

Author

Chumbita, Mariana, primary, Puerta-Alcalde, Pedro, additional, Yáñez, Lucrecia, additional, Angeles Cuesta, Maria, additional, Chinea, Anabelle, additional, Español-Morales, Ignacio, additional, Fernandez-Abellán, Pascual, additional, Gudiol, Carlota, additional, González-Sierra, Pedro, additional, Rojas, Rafael, additional, Sánchez-Pina, José María, additional, Vadillo, Irene Sánchez, additional, Sánchez, Miguel, additional, Varela, Rosario, additional, Vázquez, Lourdes, additional, Guerreiro, Manuel, additional, Monzo, Patricia, additional, Lopera, Carlos, additional, Aiello, Tommaso Francesco, additional, Peyrony, Oliver, additional, Soriano, Alex, additional, and Garcia-Vidal, Carolina, additional

Published
2023
Full Text
View/download PDF

18. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure

Author

Jiménez-Ubieto, Ana, Grande, Carlos, Caballero, Dolores, Yáñez, Lucrecia, Novelli, Silvana, Hernández-Garcia, Miguel Teodoro, Manzanares, María, Arranz, Reyes, Ferreiro, José Javier, Bobillo, Sabella, Mercadal, Santiago, Galeo, Andrea, López Jiménez, Javier, Moraleda, José María, Vallejo, Carlos, Albo, Carmen, Pérez, Elena, Marrero, Carmen, Magnano, Laura, Palomera, Luis, Jarque, Isidro, Martínez-Sánchez, Pilar, Martín, Alejandro, Coria, Erika, López-Guillermo, Armando, Salar, Antonio, and Lahuerta, Juan José

Published
2017
Full Text
View/download PDF

19. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT

Author

Heidenreich, Silke, Ziagkos, Dimitris, de Wreede, Liesbeth C., van Biezen, Anja, Finke, Jürgen, Platzbecker, Uwe, Niederwieser, Dietger, Einsele, Hermann, Bethge, Wolfgang, Schleuning, Michael, Beelen, Dietrich W., Tischer, Johanna, Nagler, Arnon, Glass, Bertram, Maertens, Johan, Yáñez, Lucrecia, Beguin, Yves, Sill, Heinz, Scheid, Christof, Stelljes, Matthias, Ganser, Arnold, Zachée, Pierre, Selleslag, Dominik, de Witte, Theo, Robin, Marie, and Kröger, Nicolaus

Published
2017
Full Text
View/download PDF

20. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

Author

Novelli, Silvana, Bento, Leyre, Garcia, Irene, Prieto, Laura, López, Lucía, Gutierrez, Gonzalo, Hernani, Rafael, Pérez, Ariadna, Esquirol, Albert, Solano, Carlos, Bastos, Mariana, Dorado, Nieves, Rodríguez, Nancy, Rodríguez, Guillermo, Piñana, Jose L., Montoro, Juan, Herrera, Pilar, Luna, Alejandro, Parody, Rocío, Martín, Carmen, García, Estefanía, López, Oriana, Heras, Inmaculada, Zanabili, Joud, Moraleda, Jose M., Yañez, Lucrecia, Gutierrez, Antonio, Zudaire, Teresa, Córdoba, Raúl, Varela, Rosario, Ferra, Christelle, Martínez, Joaquin, Martínez, Carmen, Gonzalez-Barca, Eva, Martino, Rodrigo, and Caballero, Dolores

Published
2021
Full Text
View/download PDF

21. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry

Author

Jiménez-Ubieto, Ana, Grande, Carlos, Caballero, Dolores, Yáñez, Lucrecia, Hernández-Garcia, Miguel Teodoro, Novelli, Silvana, Arranz, Reyes, Ferreiro, José Javier, Bobillo, Sabella, Mercadal, Santiago, Galeo, Andrea, Jiménez, Javier López, Moraleda, José María, Vallejo, Carlos, Albo, Carmen, Pérez, Elena, Marrero, Carmen, Magnano, Laura, Palomera, Luis, Jarque, Isidro, Martínez-Sánchez, Pilar, Martín, Alejandro, Coria, Erika, López-Guillermo, Armando, Salar, Antonio, Lahuerta, Juan José, and on behalf of the GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.

Published
2018
Full Text
View/download PDF

22. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

Author

Mussetti, Alberto, primary, Bento, Leyre, additional, Bastos-Oreiro, Mariana, additional, Rius-Sansalvador, Blanca, additional, Albo, Carmen, additional, Bailen, Rebeca, additional, Barba, Pere, additional, Benzaquén, Ana, additional, Briones, Javier, additional, Caballero, Ana Carolina, additional, Campos, António, additional, Español, Ignacio, additional, Ferra, Christelle, additional, López, Sebastián Garzón, additional, González Sierra, Pedro Antonio, additional, Guerra, Luisa Maria, additional, Hernani, Rafael, additional, Iacoboni, Gloria, additional, Jiménez-Ubieto, Ana, additional, Kwon, Mi, additional, Corral, Lucía López, additional, López-Godino, Oriana, additional, Munoz, Maria Carmen Martinez, additional, Martínez-Cibrián, Nuria, additional, Gómez, Juan Montoro, additional, Pérez-Ortega, Laura, additional, Ortí, Guillermo, additional, Ortiz-Maldonado, Valentín, additional, Pascual, Maria-Jesús, additional, Perera, María, additional, Perez, Antonio, additional, Reguera, Juan Luis, additional, Sanchez, Jose M., additional, Sanz, Jaime, additional, Torrent, Anna, additional, Yáñez, Lucrecia, additional, Varela, Rosario, additional, Echechipia, Izaksun Ceberio, additional, Caballero, Dolores, additional, and Sureda, Anna, additional

Published
2023
Full Text
View/download PDF

23. Recommendations on the use of azole antifungals in hematology-oncology patients

Author

Azanza, José Ramón, primary, Mensa, José, additional, Barberán, José, additional, Vázquez, Lourdes, additional, Pérez de Oteyza, Jaime, additional, Kwon, Mi, additional, Yáñez, Lucrecia, additional, Aguado, José María, additional, Cubillo Gracian, Antonio, additional, Solano, Carlos, additional, Ruiz Camps, Isabel, additional, Fortún, Jesús, additional, Salavert Lletí, Miguel, additional, Gudiol, Carlota, additional, Olave Rubio, Teresa, additional, García-Vidal, Carolina, additional, Rovira Tarrats, Montserrat, additional, Suárez-Lledó Grande, María, additional, González-Sierra, Pedro, additional, and Dueñas Gutiérrez, Carlos, additional

Published
2023
Full Text
View/download PDF

24. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

Author

Generalitat de Catalunya, Mussetti, Alberto, Bento, Leyre, Bastos-Oreiro, Mariana, Rius-Sansalvador, Blanca, Albo, Carmen, Bailen, Rebeca, Barba, Pere, Benzaquén, Ana, Briones, Javier, Caballero, Ana Carolina, Campos, Antonio, Español, Ignacio, Ferrá, Christelle, Garzón López, Sebastián, González-Sierra, Pedro Antonio, Guerra, Luisa María, Hernani, Rafael, Iacoboni, Gloria, Jiménez-Ubieto, Ana, Kwon, Mi, López-Corral, Lucía, López-Godino, Oriana, Martínez, Carmen, Martínez-Cibrián, Nuria, Montoro, Juan, Pérez-Ortega, Laura, Ortí, Guillermo, Valentín Ortiz-Maldonado, Pascual, M. Jesús, Perera, María, Pérez, Antonio, Reguera, Juan Luis, Sánchez, José M., Sanz, Jaime, Torrent, Anna, Yáñez, Lucrecia, Varela, Rosario, Ceberio-Echechipia, Izaksun, Caballero, Dolores, Sureda, Anna, Generalitat de Catalunya, Mussetti, Alberto, Bento, Leyre, Bastos-Oreiro, Mariana, Rius-Sansalvador, Blanca, Albo, Carmen, Bailen, Rebeca, Barba, Pere, Benzaquén, Ana, Briones, Javier, Caballero, Ana Carolina, Campos, Antonio, Español, Ignacio, Ferrá, Christelle, Garzón López, Sebastián, González-Sierra, Pedro Antonio, Guerra, Luisa María, Hernani, Rafael, Iacoboni, Gloria, Jiménez-Ubieto, Ana, Kwon, Mi, López-Corral, Lucía, López-Godino, Oriana, Martínez, Carmen, Martínez-Cibrián, Nuria, Montoro, Juan, Pérez-Ortega, Laura, Ortí, Guillermo, Valentín Ortiz-Maldonado, Pascual, M. Jesús, Perera, María, Pérez, Antonio, Reguera, Juan Luis, Sánchez, José M., Sanz, Jaime, Torrent, Anna, Yáñez, Lucrecia, Varela, Rosario, Ceberio-Echechipia, Izaksun, Caballero, Dolores, and Sureda, Anna

Abstract

Anti-CD19 chimeric antigen receptor T cells (CART) has rapidly been adopted as the standard third-line therapy to treat aggressive B-cell lymphomas (ABCL) after failure of second-line therapy despite the lack of direct comparisons with allogeneic hematopoietic cell transplantation (alloHCT)-based strategies. Using the Grupo Español de Trasplante y Terapia Celular (GETH-TC) registry, we selected patients with the following characteristics: CART or alloHCT performed between 2016 and 2021; ≥18 years old; ABCL diagnosis; ≥2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse. The analysis included a total of 316 (CART = 215, alloHCT = 101) patients. Median follow-up was 15 and 36 months for the CART and alloHCT cohorts, respectively. In the multivariate analysis, CART was confirmed to be similar to alloHCT for the primary study endpoint (progression-free survival) (hazard ratio [HR] 0.92, CI95%:0.56–1.51, p = 0.75). Furthermore, when the analysis was limited to only patients with chemo-sensitive diseases (complete and partial response) at infusion (CART = 26, alloHCT=93), no differences were reported (progression-free survival at month +18: 65% versus 55%, p = 0.59). However, CART had lower non-relapse mortality (HR 0.34, 95% CI: 0.13–0.85, p = 0.02). Given the lower toxicity and similar survival outcomes, these results suggest the use of CART before alloHCT.

Published
2023

25. Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study

Author

Gilead Sciences, Instituto de Salud Carlos III, European Commission, Puerta-Alcalde, Pedro, Monzó-Gallo, Patricia, Aguilar Guisado, Manuela, Ramos, Juan Carlos, Laporte-Amargós, Júlia, Machado, Marina, Martín-Dávila, Pilar, Franch-Sarto, Mireia, Sánchez-Romero, Isabel, Badiola, Jon, Gómez, Lucia, Ruiz-Camps, Isabel, Yáñez, Lucrecia, Vázquez, Lourdes, Chumbita, Mariana, Marco, Francesc, Soriano, Álex, González, Pedro, Fernández-Cruz, Ana, Batlle, Montserrat, Fortún, Jesús, Guinea, Jesús, Gudiol, Carlota, García, Julio, Ruiz Pérez de Pipaón, Maite, Alastruey-Izquierdo, Ana, García-Vidal, Carolina, Gilead Sciences, Instituto de Salud Carlos III, European Commission, Puerta-Alcalde, Pedro, Monzó-Gallo, Patricia, Aguilar Guisado, Manuela, Ramos, Juan Carlos, Laporte-Amargós, Júlia, Machado, Marina, Martín-Dávila, Pilar, Franch-Sarto, Mireia, Sánchez-Romero, Isabel, Badiola, Jon, Gómez, Lucia, Ruiz-Camps, Isabel, Yáñez, Lucrecia, Vázquez, Lourdes, Chumbita, Mariana, Marco, Francesc, Soriano, Álex, González, Pedro, Fernández-Cruz, Ana, Batlle, Montserrat, Fortún, Jesús, Guinea, Jesús, Gudiol, Carlota, García, Julio, Ruiz Pérez de Pipaón, Maite, Alastruey-Izquierdo, Ana, and García-Vidal, Carolina

Abstract

[Objectives] We describe the current epidemiology, causes, and outcomes of breakthrough invasive fungal infections (BtIFI) in patients with haematologic malignancies., [Methods] BtIFI in patients with ≥ 7 days of prior antifungals were prospectively diagnosed (36 months across 13 Spanish hospitals) according to revised EORTC/MSG definitions., [Results] 121 episodes of BtIFI were documented, of which 41 (33.9%) were proven; 53 (43.8%), probable; and 27 (22.3%), possible. The most frequent prior antifungals included posaconazole (32.2%), echinocandins (28.9%) and fluconazole (24.8%)—mainly for primary prophylaxis (81%). The most common haematologic malignancy was acute leukaemia (64.5%), and 59 (48.8%) patients had undergone a hematopoietic stem-cell transplantation. Invasive aspergillosis, principally caused by non-fumigatus Aspergillus, was the most frequent BtIFI with 55 (45.5%) episodes recorded, followed by candidemia (23, 19%), mucormycosis (7, 5.8%), other moulds (6, 5%) and other yeasts (5, 4.1%). Azole resistance/non-susceptibility was commonly found. Prior antifungal therapy widely determined BtIFI epidemiology. The most common cause of BtIFI in proven and probable cases was the lack of activity of the prior antifungal (63, 67.0%). At diagnosis, antifungal therapy was mostly changed (90.9%), mainly to liposomal amphotericin-B (48.8%). Overall, 100-day mortality was 47.1%; BtIFI was either the cause or an essential contributing factor to death in 61.4% of cases., [Conclusions] BtIFI are mainly caused by non-fumigatus Aspergillus, non-albicans Candida, Mucorales and other rare species of mould and yeast. Prior antifungals determine the epidemiology of BtIFI. The exceedingly high mortality due to BtIFI warrants an aggressive diagnostic approach and early initiation of broad-spectrum antifungals different than those previously used.

Published
2023

26. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico

Author

Orti, Guillermo, Sanz, Jaime, Bermudez, Arancha, Caballero, Dolores, Martinez, Carmen, Sierra, Jorge, Cabrera Marin, José R., Espigado, Ildefonso, Solano, Carlos, Ferrà, Christelle, García-Noblejas, Ana, Jimenez, Santiago, Sampol, Antonia, Yañez, Lucrecia, García-Gutiérrez, Valentin, Pascual, Maria Jesus, Jurado, Manuel, Moraleda, José M., Valcarcel, David, Sanz, Miguel A., Carreras, Enric, and Duarte, Rafael F.

Published
2016
Full Text
View/download PDF

28. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

Author

Mussetti, Alberto, primary, Bento, Leyre, additional, Bastos-Oreiro, Mariana, additional, Rius.Sansalvador, B., additional, Albo, Carmen, additional, Bailen, Rebeca, additional, Barba, Pere, additional, Benzaquén, Ana, additional, Briones, Javier, additional, Caballero, Ana Carolina, additional, Campos, António, additional, Español, Ignacio, additional, Ferra, Christelle, additional, López, Sebastián Garzón, additional, González Sierra, Pedro Antonio, additional, Guerra, Luisa Maria, additional, Hernani, Rafael, additional, Iacoboni, Gloria, additional, Jiminez Ubieto, Ana Isabel, additional, Kwon, Mi, additional, Corral, Lucía López, additional, López-Godino, Oriana, additional, Munoz, Maria Carmen Martinez, additional, Martínez-Cibrián, Nuria, additional, Gómez, Juan Montoro, additional, Pérez-Ortega, Laura, additional, Ortí, Guillermo, additional, Ortiz-Maldonado, Valentín, additional, Pascual, Maria-Jesús, additional, Perera, María, additional, Perez, Antonio, additional, Reguera, Juan Luis, additional, Sanchez, Jose M., additional, Sanz, Jaime, additional, Torrent, Anna, additional, Yáñez, Lucrecia, additional, Varela, Rosario, additional, Echechipia, Izaksun Ceberio, additional, Caballero, Dolores, additional, and Sureda, Anna, additional

Published
2023
Full Text
View/download PDF

29. Long-Term Outcome of Low Dose of Anti-t-Lymphocyte Globulin in the Prophylaxis of Graft-Versus-Host Disease in Unrelated Myeloablative Hematopoietic Stem Cell Transplantation

Author

Cerezo, Juan Manuel, primary, Bermudez, Maria Aranzazu, additional, Martin Lorenzana, David, additional, Fenandez Luis, Sara, additional, Yáñez, Lucrecia, additional, Colorado, Mercedes, additional, Sánchez Escamilla, Miriam, additional, Romón, Iñigo, additional, Arroyo, Jose Luis, additional, Martín Sánchez, Guillermo, additional, and Ocio, Enrique M., additional

Published
2022
Full Text
View/download PDF

30. Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Author

Mussetti, Alberto, primary, Bento, Leyre, additional, Bastos-Oreiro, Mariana, additional, Albo, Carmen, additional, Bailen, Rebeca, additional, Barba, Pere, additional, Benzaquén, Ana, additional, Briones, Javier, additional, Caballero, Ana Carolina, additional, Campos, António, additional, Español, Ignacio, additional, Ferra, Christelle, additional, Garzón López, Sebastián, additional, González Sierra, Pedro Antonio, additional, Guerra, Luisa Maria, additional, Hernani, Rafael, additional, Iacoboni, Gloria, additional, Jiminez Ubieto, Ana Isabel, additional, Kwon, Mi, additional, López Corral, Lucía, additional, López-Godino, Oriana, additional, Martinez Munoz, Maria Carmen, additional, Martínez-Cibrián, Nuria, additional, Montoro Gómez, Juan, additional, Pérez-Ortega, Laura, additional, Ortí, Guillermo, additional, Ortiz-Maldonado, Valentín, additional, Pascual, Maria-Jesús, additional, Perera, María, additional, Perez, Antonio, additional, Reguera, Juan Luis, additional, Sanchez, Jose M., additional, Sanz, Jaime, additional, Torrent, Anna, additional, Yáñez, Lucrecia, additional, Varela, Rosario, additional, Ceberio Echechipia, Izaksun, additional, Caballero, Dolores, additional, and Sureda, Anna, additional

Published
2022
Full Text
View/download PDF

31. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, primary, Scarfò, Lydia, additional, Chatzikonstantinou, Thomas, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Andres, Martin, additional, Antic, Darko, additional, Allsup, David, additional, Baile, Mónica, additional, Bron, Dominique, additional, Capasso, Antonella, additional, Catherwood, Mark, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Delgado, Julio, additional, Dimou, Maria, additional, Doubek, Michael, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Efstathopoulou, Maria, additional, Shimaa, El-Ashwah, additional, Enrico, Alicia, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Furstenau, Moritz, additional, Garcia-Marco, Jose A., additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Maria, Gomes da Silva, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernandez, jose Angel, additional, Herold, Tobias, additional, Iyengar, Sunil, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Olga, additional, Kalicinska, Elzbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark-David, additional, Lista, Enrico, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet Palomanes, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca Romana, additional, Mayor-Bastida, Carlota, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Milosevic, Ivana, additional, Miras Calvo, Fatima, additional, Niemann, Carsten Utoft, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Pocali, Barbara, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Raa, Doreen te, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca Ciocan, Oana, additional, Tadmor, Tamar, additional, Vandenberghe, Elisabeth, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Van Der Spek, Ellen, additional, Van Gelder, Michel, additional, Wasik-Szczepanek, Ewa, additional, Yáñez, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Eichhorst, Barbara, additional, Rambaldi, Alessandro, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2022
Full Text
View/download PDF

32. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Author

Ferra, Christelle, primary, Terol, María José, additional, Marquet Palomanes, Juan, additional, Ramírez Payer, Angel, additional, Moreno, Carol, additional, Osorio, Santiago, additional, De la Cruz, Fátima, additional, Garcia-Marco, Jose A., additional, Ortiz, Macarena, additional, Rios Herranz, Eduardo, additional, Magnano, Laura, additional, Iraheta, Sandra, additional, Puerta, Jose Manuel, additional, de la Serna, Javier, additional, Smucler, Alicia, additional, Arguiñano, Jose Maria, additional, Loscertales, Javier, additional, Muiña, Begoña, additional, Fernández, Rubén, additional, García, Tomas, additional, Márquez, José A., additional, Muntañola Prat, Ana, additional, Perez Persona, Ernesto, additional, Yáñez, Lucrecia, additional, Pérez-Encinas, Manuel, additional, González Díaz, Marcos, additional, Caballero, Gonzalo, additional, Andreu, María Angeles, additional, Andreu, Rafael, additional, Ruiz-Zorrilla, Ana, additional, Moreno, Diana, additional, and Baltasar, Patricia, additional

Published
2022
Full Text
View/download PDF

33. Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors

Author

Royo-Cebrecos, Cristina, Laporte-Amargós, Julia, Peña, Marta, Ruiz-Camps, Isabel, Puerta-Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, Miguel, Mikulska, Malgorzata, Martín-Dávila, Pilar, Herrera, Fabian, Gasch, Oriol, Drgona, Lubos, Morales, Hugo Manuel Paz, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried V, Palacios-Baena, Zaira R, de la Calle, Guillermo Maestro, Montero, Maria Milagro, Kanj, Souha S, Sipahi, Oguz R, Calik, Sebnem, Márquez-Gómez, Ignacio, Marin, Jorge I, Gomes, Marisa Z R, Hemmatti, Philipp, Araos, Rafael, Peghin, Maddalena, Del Pozo, José Luis, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andrés, Carratalà, Jordi, Gudiol, Carlota, IRONIC study group, and Universidad de Cantabria

Subjects
Microbiology (medical), Adult, Neutropenic Patients, Pseudomonas aeruginosa, bacteremia, bloodstream infection, cancer, solid tumor, hematologic malignancy, Resistance, Gram-Negative Bacilli, Bacteremia, Bloodstream infection, Immunology and Allergy, Risk-Factors, Hematologic malignanc, Mortality, Càncer, Molecular Biology, Tumors, Cancer, General Immunology and Microbiology, Solid tumor, Infectious Diseases, Therapy
Abstract

Objectives: To assess the clinical features and outcomes of Pseudomonas aeruginosa bloodstream infection (PA BSI) in neutropenic patients with hematological malignancies (HM) and with solid tumors (ST), and identify the risk factors for 30-day mortality. Methods: We performed a large multicenter, retrospective cohort study including onco-hematological neutropenic patients with PA BSI conducted across 34 centers in 12 countries (January 2006-May 2018). Episodes occurring in hematologic patients were compared to those developing in patients with ST. Risk factors associated with 30-day mortality were investigated in both groups. Results: Of 1217 episodes of PA BSI, 917 occurred in patients with HM and 300 in patients with ST. Hematological patients had more commonly profound neutropenia (0.1 x 10(9) cells/mm) (67% vs. 44.6%; p < 0.001), and a high risk Multinational Association for Supportive Care in Cancer (MASCC) index score (32.2% vs. 26.7%; p = 0.05). Catheter-infection (10.7% vs. 4.7%; p = 0.001), mucositis (2.4% vs. 0.7%; p = 0.042), and perianal infection (3.6% vs. 0.3%; p = 0.001) predominated as BSI sources in the hematological patients, whereas pneumonia (22.9% vs. 33.7%; p < 0.001) and other abdominal sites (2.8% vs. 6.3%; p = 0.006) were more common in patients with ST. Hematological patients had more frequent BSI due to multidrug-resistant P. aeruginosa (MDRPA) (23.2% vs. 7.7%; p < 0.001), and were more likely to receive inadequate initial antibiotic therapy (IEAT) (20.1% vs. 12%; p < 0.001). Patients with ST presented more frequently with septic shock (45.8% vs. 30%; p < 0.001), and presented worse outcomes, with increased 7-day (38% vs. 24.2%; p < 0.001) and 30-day (49% vs. 37.3%; p < 0.001) case-fatality rates. Risk factors for 30-day mortality in hematologic patients were high risk MASCC index score, IEAT, pneumonia, infection due to MDRPA, and septic shock. Risk factors for 30-day mortality in patients with ST were high risk MASCC index score, IEAT, persistent BSI, and septic shock. Therapy with granulocyte colony-stimulating factor was associated with survival in both groups. Conclusions: The clinical features and outcomes of PA BSI in neutropenic cancer patients showed some differences depending on the underlying malignancy. Considering these differences and the risk factors for mortality may be useful to optimize their therapeutic management. Among the risk factors associated with overall mortality, IEAT and the administration of granulocyte colony-stimulating factor were the only modifiable variables., ESCMID Study Group for Immunocompromised Hosts (ESGICH); Spanish Network for Research in Infectious Diseases; Rio Hortega program of the Instituto de Salud Carlos III; ESCMID Study Group for Bloodstream Infections, Endocarditis, and Sepsis (ESGBIES), We thank the ESCMID Study Group for Bloodstream Infections, Endocarditis, and Sepsis (ESGBIES) and the ESCMID Study Group for Immunocompromised Hosts (ESGICH) for supporting the study. We thank the Centres de Recerca de Catalunya (CERCA) Program and Generalitat de Catalunya for the institutional support. We thank the Spanish Network for Research in Infectious Diseases and the Rio Hortega program of the Instituto de Salud Carlos III for the financial support of pre-doctoral student J. Laporte-Amargos and A. Bergas.

Published
2022

34. Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors

Author

Royo-Cebrecos, Cristina, primary, Laporte-Amargós, Julia, additional, Peña, Marta, additional, Ruiz-Camps, Isabel, additional, Puerta-Alcalde, Pedro, additional, Abdala, Edson, additional, Oltolini, Chiara, additional, Akova, Murat, additional, Montejo, Miguel, additional, Mikulska, Malgorzata, additional, Martín-Dávila, Pilar, additional, Herrera, Fabian, additional, Gasch, Oriol, additional, Drgona, Lubos, additional, Morales, Hugo Manuel Paz, additional, Brunel, Anne-Sophie, additional, García, Estefanía, additional, Isler, Burcu, additional, Kern, Winfried V., additional, Palacios-Baena, Zaira R., additional, de la Calle, Guillermo Maestro, additional, Montero, Maria Milagro, additional, Kanj, Souha S., additional, Sipahi, Oguz R., additional, Calik, Sebnem, additional, Márquez-Gómez, Ignacio, additional, Marin, Jorge I., additional, Gomes, Marisa Z. R., additional, Hemmatti, Philipp, additional, Araos, Rafael, additional, Peghin, Maddalena, additional, del Pozo, José Luis, additional, Yáñez, Lucrecia, additional, Tilley, Robert, additional, Manzur, Adriana, additional, Novo, Andrés, additional, Carratalà, Jordi, additional, and Gudiol, Carlota, additional

Published
2022
Full Text
View/download PDF

35. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

Author

Albasanz Puig, Adaia, Durà Miralles, Xavier, Laporte Amargós, Júlia, Mussetti, Alberto, Ruiz Camps, Isabel, Puerta Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, José Miguel, Mikulska, Malgorzata, Martín Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Morales, Hugo Manuel Paz, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried V., Retamar Gentil, Pilar, Aguado García, José María, Montero, Milagros, Kanj, Souha S., Sipahi, Oguz R., Calik, Sebnem, Márquez Gómez, Ignacio, Marin, Jorge I., Gomes, Marisa Z. R., Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Pozo, José Luis del, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andres, Pallarès, Natàlia, Bergas, Alba, Carratalà, Jordi, Gudiol, Carlota, Albasanz Puig, Adaia, Durà Miralles, Xavier, Laporte Amargós, Júlia, Mussetti, Alberto, Ruiz Camps, Isabel, Puerta Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, José Miguel, Mikulska, Malgorzata, Martín Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Morales, Hugo Manuel Paz, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried V., Retamar Gentil, Pilar, Aguado García, José María, Montero, Milagros, Kanj, Souha S., Sipahi, Oguz R., Calik, Sebnem, Márquez Gómez, Ignacio, Marin, Jorge I., Gomes, Marisa Z. R., Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Pozo, José Luis del, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andres, Pallarès, Natàlia, Bergas, Alba, Carratalà, Jordi, and Gudiol, Carlota

Abstract

To assess the effect of combination antibiotic empirical therapy on 30-day case-fatality rate in neutropenic cancer patients with Pseudomonas aeruginosa (PA) bacteremic pneumonia. This was a multinational, retrospective cohort study of neutropenic onco-hematological patients with PA bloodstream infection (BSI) (2006–2018). The effect of appropriate empirical combination therapy, appropriate monotherapy and inappropriate empirical antibiotic therapy [IEAT] on 30-day case-fatality was assessed only in patients with PA bacteremic pneumonia. Among 1017 PA BSI episodes, pneumonia was the source of BSI in 294 (28.9%). Among those, 52 (17.7%) were caused by a multidrug-resistant (MDR) strain and 68 (23.1%) received IEAT, mainly when the infection was caused by an MDR strain [38/52 (73.1%) vs. 30/242 (12.4%); p < 0.001]. The 30-day case-fatality rate was higher in patients with PA bacteremic pneumonia than in those with PA BSI from other sources (55.1% vs. 31.4%; p < 0.001). IEAT was associated with increased 30-day case-fatality (aHR 1.44 [95%CI 1.01–2.03]; p = 0.042), whereas the use of appropriate combination empirical treatment was independently associated with improved survival (aHR 0.46 [95%CI 0.27–0.78]; p = 0.004). Appropriate empirical monotherapy was not associated with improved overall survival (aHR 1.25 [95%CI 0.76–2.05]; p = 0.39). Combination antibiotic empirical therapy should be administered promptly in febrile neutropenic patients with suspected pneumonia as the source of infection., Instituto de Salud Carlos III (ISCIII)/ Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2022

36. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

Author

Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (España), European Society of Clinical Microbiology and Infectious Diseases, Generalitat de Catalunya, Albasanz-Puig, Adaia, Durà-Miralles, Xavier, Laporte-Amargós, Júlia, Mussetti, Alberto, Ruiz-Camps, Isabel, Puerta-Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, Miguel, Mikulska, Malgorzata, Martín-Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Paz Morales, Hugo Manuel, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried, Retamar Gentil, Pilar, Aguado, José María, Montero, Milagros, Kanj, Souha S., Sipahi, Oguz Resat, Calik, Sebnem, Márquez-Gómez, Ignacio, Marin, Jorge Iván, Gomes, Marisa Z. R., Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Pozo, José Luis del, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andres, Pallarès, Natàlia, Bergas, Alba, Carratalà, Jordi, Gudiol, Carlota, Ironic Study Group, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (España), European Society of Clinical Microbiology and Infectious Diseases, Generalitat de Catalunya, Albasanz-Puig, Adaia, Durà-Miralles, Xavier, Laporte-Amargós, Júlia, Mussetti, Alberto, Ruiz-Camps, Isabel, Puerta-Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, Miguel, Mikulska, Malgorzata, Martín-Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Paz Morales, Hugo Manuel, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried, Retamar Gentil, Pilar, Aguado, José María, Montero, Milagros, Kanj, Souha S., Sipahi, Oguz Resat, Calik, Sebnem, Márquez-Gómez, Ignacio, Marin, Jorge Iván, Gomes, Marisa Z. R., Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Pozo, José Luis del, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andres, Pallarès, Natàlia, Bergas, Alba, Carratalà, Jordi, Gudiol, Carlota, and Ironic Study Group

Abstract

To assess the effect of combination antibiotic empirical therapy on 30-day case-fatality rate in neutropenic cancer patients with Pseudomonas aeruginosa (PA) bacteremic pneumonia. This was a multinational, retrospective cohort study of neutropenic onco-hematological patients with PA bloodstream infection (BSI) (2006−2018). The effect of appropriate empirical combination therapy, appropriate monotherapy and inappropriate empirical antibiotic therapy [IEAT] on 30-day case-fatality was assessed only in patients with PA bacteremic pneumonia. Among 1017 PA BSI episodes, pneumonia was the source of BSI in 294 (28.9%). Among those, 52 (17.7%) were caused by a multidrug-resistant (MDR) strain and 68 (23.1%) received IEAT, mainly when the infection was caused by an MDR strain [38/52 (73.1%) vs. 30/242 (12.4%); p < 0.001]. The 30-day case-fatality rate was higher in patients with PA bacteremic pneumonia than in those with PA BSI from other sources (55.1% vs. 31.4%; p < 0.001). IEAT was associated with increased 30-day case-fatality (aHR 1.44 [95%CI 1.01−2.03]; p = 0.042), whereas the use of appropriate combination empirical treatment was independently associated with improved survival (aHR 0.46 [95%CI 0.27−0.78]; p = 0.004). Appropriate empirical monotherapy was not associated with improved overall survival (aHR 1.25 [95%CI 0.76−2.05]; p = 0.39). Combination antibiotic empirical therapy should be administered promptly in febrile neutropenic patients with suspected pneumonia as the source of infection.

Published
2022

37. Recommendations on the use of azole antifungals in hematology-oncology patients.

Author

Ramón Azanza, José, Mensa, José, Barberán, José, Vázquez, Lourdes, Pérez de Oteyza, Jaime, Kwon, Mi, Yáñez, Lucrecia, María Aguado, José, Cubillo Gracian, Antonio, Solano, Carlos, Ruiz Camps, Isabel, Fortún, Jesús, Lletí, Miguel Salavert, Gudiol, Carlota, Olave Rubio, Teresa, García-Vidal, Carolina, Rovira Tarrats, Montserrat, Suárez-Lledó Grande, María, González-Sierra, Pedro, and Dueñas Gutiérrez, Carlos

Subjects
AZOLES, ANTIFUNGAL agents, HEMATOLOGY, ARSENIC, VENETOCLAX
Abstract

Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

38. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia

Author

Albasanz-Puig, Adaia, Durà-Miralles, Xavier, Laporte-Amargós, Júlia, Mussetti, Alberto, Ruiz-Camps, Isabel, Puerta-Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, José Miguel, Mikulska, Malgorzata, Martín-Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Morales, Hugo Manuel Paz, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried V, Retamar-Gentil, Pilar, Aguado, José María, Montero, Milagros, Kanj, Souha S, Sipahi, Oguz R, Calik, Sebnem, Márquez-Gómez, Ignacio, Marin, Jorge I, Gomes, Marisa Z R, Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Del Pozo, José Luis, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andres, Pallarès, Natàlia, Bergas, Alba, Carratalà, Jordi, Gudiol, Carlota, On Behalf Of The Ironic Study Group, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (España), European Society of Clinical Microbiology and Infectious Diseases, and Generalitat de Catalunya

Subjects
Microbiology (medical), Hematologic Malignancies, Resistance, Pseudomonas aeruginosa, bloodstream infection, pneumonia, septic shock, neutropenia, Pneumònia, Antibiòtics, Bacteremia, Guidelines, Monotherapy, Microbiology, Oncología, Infectious-Diseases Society, Antibiotics, Virology, Risk-Factors
Abstract

To assess the effect of combination antibiotic empirical therapy on 30-day case-fatality rate in neutropenic cancer patients with Pseudomonas aeruginosa (PA) bacteremic pneumonia. This was a multinational, retrospective cohort study of neutropenic onco-hematological patients with PA bloodstream infection (BSI) (2006-2018). The effect of appropriate empirical combination therapy, appropriate monotherapy and inappropriate empirical antibiotic therapy [IEAT] on 30-day case-fatality was assessed only in patients with PA bacteremic pneumonia. Among 1017 PA BSI episodes, pneumonia was the source of BSI in 294 (28.9%). Among those, 52 (17.7%) were caused by a multidrug-resistant (MDR) strain and 68 (23.1%) received IEAT, mainly when the infection was caused by an MDR strain [38/52 (73.1%) vs. 30/242 (12.4%); p < 0.001]. The 30-day case-fatality rate was higher in patients with PA bacteremic pneumonia than in those with PA BSI from other sources (55.1% vs. 31.4%; p < 0.001). IEAT was associated with increased 30-day case-fatality (aHR 1.44 [95%CI 1.01-2.03]; p = 0.042), whereas the use of appropriate combination empirical treatment was independently associated with improved survival (aHR 0.46 [95%CI 0.27-0.78]; p = 0.004). Appropriate empirical monotherapy was not associated with improved overall survival (aHR 1.25 [95%CI 0.76-2.05]; p = 0.39). Combination antibiotic empirical therapy should be administered promptly in febrile neutropenic patients with suspected pneumonia as the source of infection., Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain [CB21/13/00009, CB21/13/00079, CB21/13/00054, CB21/13/00086, CB21/13/00012], This work was supported by the Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas (CIBERINFEC) [CB21/13/00009, CB21/13/00079, CB21/13/00054, CB21/13/00086, CB21/13/00012], Madrid, Spain.

Published
2022
Full Text
View/download PDF

41. Low Rate of Infectious Enterocolitis in Allogeneic Stem Cell Transplant Recipients with Acute Diarrhea: A Prospective Study by the GETH-TC.

Author

Velao, Sara Redondo, Garcia Cadenas, Irene, Cuesta, Mª Angeles, Sanchez-Ortega, Isabel, Fernández-Avilés, Francesc, Roldan, Elisa, Torrent, Anna, Viguria, M. Cruz, Villar, Sara, Bento, Leyre, Yáñez, Lucrecia, Martino, Rodrigo, and Piñana, Jose Luis

Subjects
STEM cell transplantation, ENTEROCOLITIS, HEMATOPOIETIC stem cell transplantation, DIARRHEA, NOSOCOMIAL infections, LONGITUDINAL method
Abstract

Acute diarrhea is a common and debilitating complication in recipients of allogeneic hematopoietic stem cell transplantation (HCT). In this prospective, observational, and multicenter study we examined all episodes occurring in the first 6 months of 142 consecutive adult patients who underwent a reduced-intensity conditioning HCT in 10 Spanish tertiary university hospitals. Fifty-four patients (38%) developed a total of 75 acute diarrhea episodes. The median time from HCT to the first episode was 38 days (4–157). The main cause of enterocolitis was lower GI-aGVHD (38%), followed by infections (21%) and drug-related toxicity (8%). Causative infectious causes were identified in only 16/75 episodes (21%). C. difficile-related infection was the most common infectious agent with an incidence and recurrence of 13% and 2%, respectively. With a median follow-up for survivors of 32 months, the non-relapse mortality (NRM) and the overall survival (OS) at 1 year, were 20% (95% C.I.: 14–28%) and 69% (95% C.I.: 61–77%), respectively. Development of enterocolitis was not associated with higher NRM (p = 0.37) or worse OS (p = 0.9). This real-life study confirms that the diagnosis and management of acute diarrhea in the early stages after HCT is challenging. Nosocomial infections seem to be relatively uncommon, probably due to more rational use of antibiotics. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Author

Baltasar, Patricia, primary, Terol, María José, additional, Marquet Palomanes, Juan, additional, Ramírez Payer, Angel, additional, Moreno, Carol, additional, Osorio, Santiago, additional, De la Cruz, Fátima, additional, Garcia-Marco, Jose A., additional, Ortiz, Macarena, additional, Ríos Herranz, Eduardo, additional, Magnano, Laura, additional, Iraheta, Sandra, additional, Puerta, Jose Manuel, additional, de la Serna, Javier, additional, Smucler Simonovich, Alicia, additional, Arguiñano, Jose Maria, additional, Loscertales, Javier, additional, Muiña, Begoña, additional, Fernandez, Ruben, additional, García, Tomas, additional, Márquez, José A., additional, Muntañola Prat, Ana, additional, Pérez Persona, Ernesto, additional, Yáñez, Lucrecia, additional, Pérez-Encinas, Manuel, additional, González Díaz, Marcos, additional, Caballero, Gonzalo, additional, Andreu, María Angeles, additional, Andreu, Rafael, additional, Ruiz-Zorrilla, Ana, additional, Moreno, Diana, additional, and Ferrà, Christelle, additional

Published
2021
Full Text
View/download PDF

43. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Author

Chatzikonstantinou, Thomas, primary, Scarfo, Lydia, additional, Demosthenous, Christos, additional, Kotaskova, Jana, additional, Iacoboni, Gloria, additional, Minga, Evangelia, additional, Chammou, Dimitra, additional, Karakatsoulis, Georgios, additional, Albi, Elisa, additional, Alcoceba, Miguel, additional, El-Ashwah, Shaimaa, additional, Bacchiarri, Francesca, additional, Khan, Mehreen Ali, additional, Aurran, Thérèse, additional, Calleja, Anne, additional, Cassin, Ramona, additional, Chatzileontiadou, Sofia, additional, Christian, Amy, additional, Claus, Rainer, additional, Collado, Rosa, additional, De Deus Santos, Marcos Daniel, additional, Davis, Zadie, additional, Dimou, Maria, additional, Donaldson, David, additional, Dos Santos, Gimena, additional, Dreta, Barbara, additional, Efstathopoulou, Maria, additional, Enrico, Alicia, additional, Fresa, Alberto, additional, Galimberti, Sara, additional, García-Serra, Rocío, additional, González-Gascón Y Marín, Isabel, additional, Gozzetti, Alessandro, additional, Guarente, Valerio, additional, Harrop, Sean, additional, Hatzimichael, Eleftheria, additional, Herishanu, Yair, additional, Inchiappa, Luca, additional, Iskas, Michalis, additional, Jaksic, Ozren, additional, Janssen, Susanne R., additional, Kalicinska, Elzbieta, additional, Karakus, Volkan, additional, Kater, Arnon P., additional, Kho, Bonnie, additional, Konstantinou, Iliana, additional, Longval, Thomas, additional, Koren-Michowitz, Maya, additional, Kotsianidis, Ioannis, additional, Kreitman, Robert J., additional, Nath, Uttam Kumar, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laribi, Kamel, additional, Levy, Ilana, additional, Lopez-Garcia, Alberto, additional, Marquet Palomanes, Juan, additional, Maslejova, Stanislava, additional, Mayor-Bastida, Carlota, additional, Merabet, Fatiha, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Miras, Fatima, additional, Moia, Riccardo, additional, Morawska, Marta, additional, Navarro-Bailón, Almudena, additional, Oscier, David, additional, Olivieri, Jacopo, additional, Papajík, Tomáš, additional, Papaioannou, Maria, additional, Pierie, Cheyenne, additional, Puiggros, Anna, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Schiattone, Luana, additional, Sevindik, Omur Gokmen, additional, Shen, Yandong, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Soliman, Dina Sameh, additional, Špaček, Martin, additional, Schiwitza, Annett, additional, Tadmor, Tamar, additional, Tourjeman, Liat, additional, Tse, Eric, additional, Visentin, Andrea, additional, Tomic, Kristina, additional, Van Gelder, Michel, additional, Vassilakopoulos, Theodoros P., additional, Vitale, Candida, additional, Vrachiolias, George, additional, Vukovic, Vojin, additional, Xu, Zhenshu, additional, Yáñez, Lucrecia, additional, Yagci, Munci, additional, Yassin, Mohamed A, additional, Zuchnicka, Jana, additional, Angelopoulou, Maria K., additional, Antic, Darko, additional, Biderman, Bella V., additional, Catherwood, Mark, additional, Coscia, Marta, additional, Cuneo, Antonio, additional, Demirkan, Fatih, additional, Espinet, Blanca, additional, Gaidano, Gianluca, additional, Guièze, Romain, additional, Kalashnikova, Olga, additional, Laurenti, Luca, additional, Mulligan, Stephen, additional, Murru, Roberta, additional, Nikitin, Eugene A., additional, Panayiotidis, Panayiotis, additional, Pangalis, Gerasimos, additional, Panovska, Irina, additional, Popov, Viola Maria, additional, Pospíšilová, Šárka, additional, Smolej, Lukas, additional, Sportoletti, Paolo, additional, Stavroyianni, Niki, additional, Tam, Constantine S., additional, Trentin, Livio, additional, Trněný, Marek, additional, Bosch Albareda, Francesc, additional, Doubek, Michael, additional, Chatzidimitriou, Anastasia, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2021
Full Text
View/download PDF

45. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

Author

González-Rincón, Julia, primary, Garcia-Vela, José A., additional, Gómez, Sagrario, additional, Fernández-Cuevas, Belén, additional, Nova-Gurumeta, Sara, additional, Pérez-Sanz, Nuria, additional, Alcoceba, Miguel, additional, González, Marcos, additional, Anguita, Eduardo, additional, López-Jiménez, Javier, additional, González-Barca, Eva, additional, Yáñez, Lucrecia, additional, Pérez-Persona, Ernesto, additional, de la Serna, Javier, additional, Fernández-Zarzoso, Miguel, additional, Deben, Guillermo, additional, Peñalver, Francisco J., additional, Fernández, María C., additional, de Oteyza, Jaime Pérez, additional, Andreu, M. Ángeles, additional, Ruíz-Guinaldo, M. Ángeles, additional, Paz-Arias, Raquel, additional, García-Malo, M. Dolores, additional, Recasens, Valle, additional, Collado, Rosa, additional, Córdoba, Raúl, additional, Navarro-Matilla, Belén, additional, Sánchez-Beato, Margarita, additional, and García-Marco, José A., additional

Published
2021
Full Text
View/download PDF

46. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

Author

Bento, Leyre, Gutiérrez, Antonio, Novelli, Silvana, Montoro, Juan, Piñana, José Luis, López-Corral, L., Cabrero, Mónica, Martín-Sancho, Alejandro, Gutiérrez-García, Gonzalo, Ortíz-Moscovich, Marcela, Bastos-Oreiro, Mariana, Dorado, Nieves, Pérez, Ariadna, Hernani, Rafael, Ferrá, Christelle, Parody, Rocío, García-Cadenas, Irene, Herrera, Pilar, Rodríguez-Real, Guillermo, Rodríguez, Nancy, Martín, Carmen, Yáñez, Lucrecia, Zanabili, Joud, Varela, María Rosario, López-Godino, Oriana, Heras, Inmaculada, Español, Ignacio, Martínez, Carmen, Pérez-Simón, José A., Solano, Carlos, Sureda, Anna, Sierra, Jordi, Sampol, Antonia, Caballero, Dolores, Bento, Leyre, Gutiérrez, Antonio, Novelli, Silvana, Montoro, Juan, Piñana, José Luis, López-Corral, L., Cabrero, Mónica, Martín-Sancho, Alejandro, Gutiérrez-García, Gonzalo, Ortíz-Moscovich, Marcela, Bastos-Oreiro, Mariana, Dorado, Nieves, Pérez, Ariadna, Hernani, Rafael, Ferrá, Christelle, Parody, Rocío, García-Cadenas, Irene, Herrera, Pilar, Rodríguez-Real, Guillermo, Rodríguez, Nancy, Martín, Carmen, Yáñez, Lucrecia, Zanabili, Joud, Varela, María Rosario, López-Godino, Oriana, Heras, Inmaculada, Español, Ignacio, Martínez, Carmen, Pérez-Simón, José A., Solano, Carlos, Sureda, Anna, Sierra, Jordi, Sampol, Antonia, and Caballero, Dolores

Abstract

We performed a retrospective multicenter study including 140 patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) from March 1995 to November 2018. Our objective was to analyze long term outcomes. Seventy-four percent had received a previous auto-SCT (ASCT) and the median number of lines pre-allo-SCT was 3 (range 1–9). Three year-event free survival (EFS) and overall survival (OS) were 38% and 44%, respectively. Non-relapse mortality (NRM) at day 100 was 19%. Cumulative incidence of grade III–IV acute graft versus host disease (GVHD) at day 100 was 16% and moderate/severe chronic GVHD at 3 years 34%. Active disease at allo-SCT (HR 1.95, p = 0.039) (HR 2.19, p = 0.019), HCT-CI ≥ 2 (2.45, p = 0.002) (HR 2.33, p = 0.006) and donor age >37 years (HR 2.75, p = 0.014) (HR 1.98, p = 0.043) were the only independent variables both for PFS and OS, respectively. NRM was significantly modified by HCT-CI ≥ 2 (HR 4.8, p = 0.008), previous ASCT (HR 4.4, p = 0.048) and grade III–IV acute GVHD on day 100 (HR 6.13, p = 0.016). Our data confirmed that allo-SCT is a curative option for patients with R/R DLBCL, displaying adequate results for fit patients with chemosensitive disease receiving an allo-SCT from a young donor.

Published
2021

47. Resistance to empirical β-lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study.

Author

Chumbita, Mariana, Puerta-Alcalde, Pedro, Yáñez, Lucrecia, Cuesta, Maria Angeles, Chinea, Anabelle, Morales, Ignacio Español, Abellán, Pascual Fernández, Gudiol, Carlota, Guerreiro, Manuel, González-Sierra, Pedro, Rojas, Rafael, Pina, José María Sánchez, Vadillo, Irene Sánchez, Varela, Rosario, Vázquez, Lourdes, Lopera, Carlos, Monzó, Patricia, Garcia-Vidal, Carolina, Español Morales, Ignacio, and Fernández Abellán, Pascual

Subjects
ANTIBIOTICS, BACTEREMIA, RESEARCH, BETA lactam antibiotics, GRAM-negative bacteria, RESEARCH methodology, NEUTROPENIA, RETROSPECTIVE studies, EVALUATION research, SEPSIS, COMPARATIVE studies, IMPACT of Event Scale, RESEARCH funding, GRAM-negative bacterial diseases, PSEUDOMONAS, BRIEF Symptom Inventory, LONGITUDINAL method
Abstract

Objectives: To describe current resistance to the β-lactams empirically recommended in the guidelines in bloodstream infection (BSI) episodes caused by Gram-negative bacilli (GNB).Methods: Retrospective, multicentre cohort study of the last 50 BSI episodes in haematological patients across 14 university hospitals in Spain. Rates of inappropriate empirical antibiotic therapy (IEAT) and impact on mortality were evaluated.Results: Of the 700 BSI episodes, 308 (44%) were caused by GNB, mainly Escherichia coli (141; 20.1%), Klebsiella spp. (56; 8%) and Pseudomonas aeruginosa (48; 6.9%). Among GNB BSI episodes, 80 (26%) were caused by MDR isolates. In those caused by Enterobacterales, 25.8% were ESBL producers and 3.5% were carbapenemase producers. Among P. aeruginosa BSI episodes, 18.8% were caused by MDR isolates. Overall, 34.7% of the isolated GNB were resistant to at least one of the three β-lactams recommended in febrile neutropenia guidelines (cefepime, piperacillin/tazobactam and meropenem). Despite extensive compliance with guideline recommendations (91.6%), 16.6% of BSI episodes caused by GNB received IEAT, which was more frequent among MDR GNB isolates (46.3% versus 6.1%; P < 0.001). Thirty day mortality was 14.6%, reaching 21.6% in patients receiving IEAT.Conclusions: Current resistance to empirical β-lactams recommended in febrile neutropenia guidelines is exceedingly high and IEAT rates are greater than desired. There is an urgent need to adapt guidelines to current epidemiology and better identify patients with a high risk of developing MDR GNB infection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Author

Muntañola, Ana, Villacampa, Guillermo, Hernández-Rivas, José Ángel, Alonso, Rosalía, Mirás, Fátima, Osorio, Santiago, Baile, Mónica, Baltasar, Patricia, López Jiménez, Javier, Hernández‑Rodríguez, Inés, Valenciano, Susana, Alfayate, Ana, Gimeno, Eva, Bárez, Abelardo, Oliveira, Ana Carla, Riaza Grau, Rosalía, Romero, Pilar, Delgado, Julio, Yáñez, Lucrecia, Zabalza, Amaya, Torres, Ana, Gómez-Roncero, María Isabel, Crespo, Marta, Córdoba, Raúl, Mateos, Juan José, Pérez, Sonia, Andreu, Rafael, Labrador, Jorge, Ruiz, María Elena, Velasquez, César Andrés, Terol, María José, Santiago, Raquel, Vidal, María Jesús, Campoy García, Fiz, Villalón, Lucía, Muiña, Begoña, Soler, Joan Alfons, Seri, Cristina, Sánchez, María José, Cuesta, Amalia, Ramos, Rafael, Sánchez‑Montalvá, Sánchez‑Montalvá, Adrán, Ruiz‑Camps, Isabel, González, Marcos, Abrisqueta, Pau, Bosch, Francesc, Abrisqueta, Pau [0000-0001-9625-7422], and Abrisqueta, Pau

Subjects
Cancer Research, 2019-20 coronavirus outbreak, medicine.medical_specialty, Leucèmia limfoide, Hematology, Coronavirus disease 2019 (COVID-19), business.industry, lcsh:RC633-647.5, Chronic lymphocytic leukemia, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), MEDLINE, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, COVID-19 (Malaltia), lcsh:RC254-282, Oncology, Internal medicine, medicine, business, Letter to the Editor
Abstract

Spain has been one the most affected countries by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic [1, 2]. Patients with chronic lymphocytic leukemia (CLL) could be at risk of more severe COVID-19 clinical forms [3] since they often carry immune perturbations aggravated by treatments used for the disease itself [4]. Two major series on patients with COVID-19 and CLL encompassing different countries and health systems reported heterogeneous factors related to the outcome [5, 6]. Herein, we are presenting the largest series of CLL patients with proved COVID-19 from a single country and Health system.

Published
2020

49. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa

Author

Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Red Española de Investigación en Patología Infecciosa, European Commission, Promex Stiftung Fur Die Forschung, Gilead Sciences, MSD, Astellas Pharma, Novartis, Pfizer, Gudiol, Carlota, Albasanz-Puig, Adaia, Laporte-Amargós, Júlia, Pallarès, Natalia, Mussetti, Alberto, Ruiz-Camps, Isabel, Puerta-Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, Miguel, Mikulska, Malgorzata, Martín-Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Paz Morales, Hugo Manuel, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried, Morales, Isabel, Maestro-de la Calle, Guillermo, Montero, Milagros, Kanj, Souha S., Sipahi, Oguz Resat, Calik, Sebnem, Márquez-Gómez, Ignacio, Marin, Jorge Iván, Gomes, Marisa Z. R., Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Pozo, José Luis del, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andrés, Carratalà, Jordi, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Red Española de Investigación en Patología Infecciosa, European Commission, Promex Stiftung Fur Die Forschung, Gilead Sciences, MSD, Astellas Pharma, Novartis, Pfizer, Gudiol, Carlota, Albasanz-Puig, Adaia, Laporte-Amargós, Júlia, Pallarès, Natalia, Mussetti, Alberto, Ruiz-Camps, Isabel, Puerta-Alcalde, Pedro, Abdala, Edson, Oltolini, Chiara, Akova, Murat, Montejo, Miguel, Mikulska, Malgorzata, Martín-Dávila, Pilar, Herrera, Fabián, Gasch, Oriol, Drgona, Lubos, Paz Morales, Hugo Manuel, Brunel, Anne-Sophie, García, Estefanía, Isler, Burcu, Kern, Winfried, Morales, Isabel, Maestro-de la Calle, Guillermo, Montero, Milagros, Kanj, Souha S., Sipahi, Oguz Resat, Calik, Sebnem, Márquez-Gómez, Ignacio, Marin, Jorge Iván, Gomes, Marisa Z. R., Hemmati, Philipp, Araos, Rafael, Peghin, Maddalena, Pozo, José Luis del, Yáñez, Lucrecia, Tilley, Robert, Manzur, Adriana, Novo, Andrés, and Carratalà, Jordi

Abstract

We aimed to assess the rate and predictive factors of bloodstream infection (BSI) due to multidrug-resistant (MDR) Pseudomonas aeruginosa in neutropenic cancer patients. We performed a multicenter, retrospective cohort study including oncohematological neutropenic patients with BSI due to P. aeruginosa conducted across 34 centers in 12 countries from January 2006 to May 2018. A mixed logistic regression model was used to estimate a model to predict the multidrug resistance of the causative pathogens. Of a total of 1,217 episodes of BSI due to P. aeruginosa, 309 episodes (25.4%) were caused by MDR strains. The rate of multidrug resistance increased significantly over the study period (P = 0.033). Predictors of MDR P. aeruginosa BSI were prior therapy with piperacillin-tazobactam (odds ratio [OR], 3.48; 95% confidence interval [CI], 2.29 to 5.30), prior antipseudomonal carbapenem use (OR, 2.53; 95% CI, 1.65 to 3.87), fluoroquinolone prophylaxis (OR, 2.99; 95% CI, 1.92 to 4.64), underlying hematological disease (OR, 2.09; 95% CI, 1.26 to 3.44), and the presence of a urinary catheter (OR, 2.54; 95% CI, 1.65 to 3.91), whereas older age (OR, 0.98; 95% CI, 0.97 to 0.99) was found to be protective. Our prediction model achieves good discrimination and calibration, thereby identifying neutropenic patients at higher risk of BSI due to MDR P. aeruginosa. The application of this model using a web-based calculator may be a simple strategy to identify high-risk patients who may benefit from the early administration of broad-spectrum antibiotic coverage against MDR strains according to the local susceptibility patterns, thus avoiding the use of broad-spectrum antibiotics in patients at a low risk of resistance development.

Published
2020

50. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Author

Abrisqueta, Pau [0000-0001-9625-7422], Muntañola, Ana, Villacampa, Guillermo, Hernández-Rivas, José Ángel, Alonso, Rosalía, Mirás, Fátima, Osorio, Santiago, Baile, Mónica, Baltasar, Patricia, López Jiménez, Javier, Hernández‑Rodríguez, Inés, Valencia, Susana, Alfayate, Ana, Gimeno, Eva, Bárez, Abelardo, Oliveira, Ana Carla, Riaza Grau, Rosalía, Romero, Pilar, Delgado, Julio, Yáñez, Lucrecia, Zabalza, Amaya, Torres, Ana, Gómez-Roncero, María Isabel, Crespo, Marta, Córdoba, Raúl, Mateos, Juan José, Pérez, Sonia, Andreu, Rafael, Labrador, Jorge, Ruiz, María Elena, Velasquez, César Andrés, Terol, María José, Santiago, Raquel, Vidal, María Jesús, Campoy García, Fiz, Villalón, Lucía, Muiña, Begoña, Soler, Joan Alfons, Seri, Cristina, Sánchez, María José, Cuesta, Amalia, Ramos, Rafael, Sánchez‑Montalvá, Sánchez‑Montalvá, Adrán, Ruiz‑Camps, Isabel, González, Marcos, Abrisqueta, Pau, Bosch, Francesc, Abrisqueta, Pau [0000-0001-9625-7422], Muntañola, Ana, Villacampa, Guillermo, Hernández-Rivas, José Ángel, Alonso, Rosalía, Mirás, Fátima, Osorio, Santiago, Baile, Mónica, Baltasar, Patricia, López Jiménez, Javier, Hernández‑Rodríguez, Inés, Valencia, Susana, Alfayate, Ana, Gimeno, Eva, Bárez, Abelardo, Oliveira, Ana Carla, Riaza Grau, Rosalía, Romero, Pilar, Delgado, Julio, Yáñez, Lucrecia, Zabalza, Amaya, Torres, Ana, Gómez-Roncero, María Isabel, Crespo, Marta, Córdoba, Raúl, Mateos, Juan José, Pérez, Sonia, Andreu, Rafael, Labrador, Jorge, Ruiz, María Elena, Velasquez, César Andrés, Terol, María José, Santiago, Raquel, Vidal, María Jesús, Campoy García, Fiz, Villalón, Lucía, Muiña, Begoña, Soler, Joan Alfons, Seri, Cristina, Sánchez, María José, Cuesta, Amalia, Ramos, Rafael, Sánchez‑Montalvá, Sánchez‑Montalvá, Adrán, Ruiz‑Camps, Isabel, González, Marcos, Abrisqueta, Pau, and Bosch, Francesc

Abstract

Spain has been one the most affected countries by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic [1, 2]. Patients with chronic lymphocytic leukemia (CLL) could be at risk of more severe COVID-19 clinical forms [3] since they often carry immune perturbations aggravated by treatments used for the disease itself [4]. Two major series on patients with COVID-19 and CLL encompassing different countries and health systems reported heterogeneous factors related to the outcome [5, 6]. Herein, we are presenting the largest series of CLL patients with proved COVID-19 from a single country and Health system.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results